Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Bio-Rad Laboratories, Inc.NYSE: BIO
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses growth accelerates
Q2 FY2026 other income / expenses of $469.5M rose 39.4% year over year, ahead of the -49.1% change in trailing-twelve-month other income / expenses.
Context
- Other income / expenses amounted to 28.1% of revenue in FY2025, down 73.7 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +39.4% holds above the trailing-twelve-month pace of -49.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 725M USD
- Year-over-year change
- +127.8%
- 4-year CAGR
- -38.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 725M | +127.8% |
| FY2024 | 2024-12-31 | (2.61B) | -119.8% |
| FY2023 | 2023-12-31 | (1.19B) | +77.1% |
| FY2022 | 2022-12-31 | (5.19B) | -204.8% |
| FY2021 | 2021-12-31 | 4.95B | — |
Other Income / Expenses vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 other income / expenses of $115.4M is the highest of the 11 companies compared; the peer median is -$55.77M.
- Its year-over-year change of -49.1% is the 5th highest of 11, against a peer median of -138.4%.
- Other income / expenses amounts to 4.5% of revenue for BIO, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $115.4M | -49.1% | — | 4.5% | |
| LTM Mar 2026 | $35.01M | -78.7% | — | 21.9% | |
| LTM Sep 2026 | $21.34M | +735.7% | -22.9% | 3.4% | |
| LTM Mar 2026 | -$9.32M | -198.2% | — | 10.8% | |
| LTM Jun 2026 | -$13.15M | -228.1% | — | 1.7% | |
| LTM Sep 2026 | -$13.45M | -269.3% | — | 1.1% | |
| LTM Jul 2026 | -$98.08M | -19.7% | — | 3.4% | |
| LTM Jun 2026 | -$154.6M | -224.8% | — | 4.4% | |
| LTM Jun 2026 | -$232.58M | -785.1% | — | 111.4% | |
| LTM Sep 2026 | -$400M | +66.4% | — | 1.6% | |
| LTM Sep 2026 | -$646M | +34.1% | — | 1.4% | |
| Peer median (excluding BIO) | -$55.77M | -138.4% | -22.9% | 3.4% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B |
| Cost of Revenue | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B |
| Gross Profit | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B |
| Gross Margin | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| Research & Development | 260.64M | 256.89M | 247.43M | 295.9M | 256.9M |
| Selling, General & Admin | 877.12M | 827.83M | 841.7M | 814M | 819.9M |
| Operating Expenses | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| EBITDA | 5.59B | (4.53B) | (654.8M) | (2.14B) | 1.21B |
| EBITDA Margin | 191.2% | -161.6% | -24.5% | -83.5% | 46.8% |
| Operating Income | 500.34M | 482.62M | 337.8M | 269M | 270.5M |
| Operating Margin | 17.1% | 17.2% | 12.6% | 10.5% | 10.5% |
| Interest Income | 18.9M | 58M | 100.9M | 82M | 95.5M |
| Interest Expense | 1.55M | 38.11M | 49.44M | 48.9M | 49M |
| Other Income / Expenses | 4.95B | (5.19B) | (1.19B) | (2.61B) | 725M |
| Income Before Tax | 5.45B | (4.7B) | (850.1M) | (2.34B) | 995.5M |
| Pre-Tax Margin | 186.4% | -167.9% | -31.8% | -91.3% | 38.5% |
| Income Tax Expense | 1.19B | (1.08B) | (212.78M) | (498.3M) | 235.6M |
| Net Income | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.9M |
| Net Margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (Basic) | 142.61 | (121.79) | (21.82) | (65.36) | 27.87 |
| EPS (Diluted) | 140.83 | (121.79) | (21.82) | (65.36) | 27.87 |
| Weighted Avg Shares | 29.83M | 29.79M | 29.21M | 28.21M | 27.26M |
| Weighted Avg Shares (Diluted) | 30.21M | 29.79M | 29.21M | 28.21M | 27.28M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.